Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$123.81
+2.7%
$132.98
$99.92
$141.23
$215.17B0.736.22 million shs19.57 million shs
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
$8.56
+6.5%
$7.96
$6.10
$28.67
$592.81M1.41400,096 shs501,623 shs
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
$1.00
-0.6%
$0.88
$0.68
$4.43
$670.19M0.62562,397 shs286,064 shs
Evotec AG stock logo
EVO
Evotec
$4.26
+0.5%
$4.13
$2.84
$5.64
$1.51B1.66136,555 shs38,466 shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.00%-6.17%-6.45%-5.49%+18.24%
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
0.00%+7.00%+15.52%+15.83%-63.37%
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
0.00%-13.04%+21.36%+2.04%-76.69%
Evotec AG stock logo
EVO
Evotec
0.00%+4.67%+7.30%+18.33%-10.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9916 of 5 stars
3.45.04.24.53.72.52.5
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
3.7225 of 5 stars
4.42.00.00.02.34.20.6
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
2.1742 of 5 stars
3.52.00.00.01.90.01.3
Evotec AG stock logo
EVO
Evotec
1.5752 of 5 stars
3.24.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.87
Moderate Buy$144.4716.69% Upside
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
2.70
Moderate Buy$24.22182.97% Upside
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
3.00
Buy$6.25525.00% Upside
Evotec AG stock logo
EVO
Evotec
2.40
Hold$5.9339.28% Upside

Current Analyst Ratings Breakdown

Latest EVO, BCYC, ABT, and CURLF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$147.00 ➝ $142.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$142.00 ➝ $141.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$148.00 ➝ $145.00
7/18/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$143.00 ➝ $145.00
7/17/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/17/2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $25.00
7/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$130.00 ➝ $140.00
7/15/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$145.00 ➝ $147.00
7/15/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$127.00 ➝ $137.00
7/8/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$140.00 ➝ $145.00
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.13$6.59 per share18.79$27.62 per share4.48
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
$35.28M16.80N/AN/A$11.48 per share0.75
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
$1.34B0.50$0.20 per share4.92$1.51 per share0.66
Evotec AG stock logo
EVO
Evotec
$862.40M1.75N/AN/A$2.91 per share1.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7115.5221.612.3532.43%18.83%10.88%N/A
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$169.03M-$3.14N/AN/AN/A-790.07%-25.54%-21.23%8/5/2025 (Estimated)
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
-$215.42M-$0.31N/AN/AN/A-17.37%-14.12%-4.40%N/A
Evotec AG stock logo
EVO
Evotec
-$212.18MN/A0.00N/AN/A-26.34%-21.51%-10.54%8/13/2025 (Estimated)

Latest EVO, BCYC, ABT, and CURLF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$0.95N/AN/AN/A$9.43 millionN/A
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.26$1.26N/A$1.01$11.01 billion$11.14 billion
5/8/2025Q1 2025
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
-$0.07-$0.07N/A-$0.08N/AN/A
5/1/2025Q1 2025
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
-$0.86-$0.88-$0.02-$0.88$8.67 million$9.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.91%N/A30.61%54 Years
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
N/AN/AN/AN/AN/A
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
N/AN/AN/AN/AN/A
Evotec AG stock logo
EVO
Evotec
N/AN/AN/AN/AN/A

Latest EVO, BCYC, ABT, and CURLF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.26
1.78
1.27
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
N/A
14.86
14.86
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
1.08
1.41
0.70
Evotec AG stock logo
EVO
Evotec
0.46
2.03
1.93

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
86.15%
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
0.03%
Evotec AG stock logo
EVO
Evotec
5.81%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
22.90%
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
N/A
Evotec AG stock logo
EVO
Evotec
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
24069.25 million53.40 millionOptionable
Curaleaf Holdings, Inc. stock logo
CURLF
Curaleaf
5,519670.19 millionN/ANot Optionable
Evotec AG stock logo
EVO
Evotec
4,827355.11 million351.56 millionNot Optionable

Recent News About These Companies

Webinar: Pharma Industry in Crisis
Evotec (NASDAQ:EVO) Shares Down 3.2% - Here's Why
Evotec (NASDAQ:EVO) Shares Gap Up - What's Next?
Evotec Receives $2.5M Grant from the Gates Foundation
Evotec SE (EVO) Q1 2025 Earnings Call Transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$123.81 +3.30 (+2.74%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$123.80 -0.01 (-0.01%)
As of 07/18/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Bicycle Therapeutics stock logo

Bicycle Therapeutics NASDAQ:BCYC

$8.56 +0.52 (+6.47%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$8.31 -0.25 (-2.92%)
As of 07/18/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Curaleaf stock logo

Curaleaf OTCMKTS:CURLF

$1.00 -0.01 (-0.60%)
As of 07/18/2025 03:57 PM Eastern

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.

Evotec stock logo

Evotec NASDAQ:EVO

$4.26 +0.02 (+0.47%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$4.28 +0.02 (+0.35%)
As of 07/18/2025 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.